NICM
RNAM

Neo Ivy Capital Management’s Avidity Biosciences RNAM Stock Holding History

Neo Ivy Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,244
Closed -$598K – 455
2025
Q1 		$598K Sell
20,244
-75,876
-79% -$2.36M 0.19% 149
2024
Q4 		$2.79M Buy
96,120
+79,524
+479% +$3.32M 0.56% 72
2024
Q3 		$762K Buy
+16,596
New +$720K 0.25% 151

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neo Ivy Capital Management's RNAM Position: Q2 2025 in Review

Neo Ivy Capital Management sold out of Avidity Biosciences (RNAM) in Q2 2025, closing a stake of 20,244 shares — an estimated $598K sold.

Neo Ivy Capital Management first reported a position in RNAM in Q3 2024 and held it in 3 quarters. The position peaked at $2.79M in Q4 2024. 206 funds tracked by Wall St. Rank hold RNAM as of Q2 2025.

  • Neo Ivy Capital Management reported no remaining Avidity Biosciences position as of Q2 2025 after selling out during the quarter.
  • Neo Ivy Capital Management sold 20,244 Avidity Biosciences shares in Q2 2025, an estimated $598K.
  • Neo Ivy Capital Management first reported a position in Avidity Biosciences in Q3 2024 and held it in 3 quarters.
  • Neo Ivy Capital Management's Avidity Biosciences position peaked at $2.79M in Q4 2024.
  • 206 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2025.

Based on Neo Ivy Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.